## 

## 

|Memorandum<br>and Articles of|Memorandum<br>and Articles of|Memorandum<br>and Articles of|Memorandum<br>and Articles of|Memorandum<br>and Articles of|Memorandum<br>and Articles of|Association.||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|The administrative<br>Information||||||required<br>to be given is|as||follows:|||||||||
|Charity Registration||||No:||266813|||||Registered|||with the Charity|Commission||for|
||||||||||||England||and Wales|||||
|Company|Registration||||No:|349408||||||||||||
|Principal<br>Offic:|and Registered|||||Starling<br>House<br>1600Bristol Parkway||North||||||||||
|||||||Bristol BS348YU||||||||||||
|Council of||Management:||||||||||||||||
|Professor||R|V Thakker|||(President)||||||||||||
|Professor||E|Device|||(General Secretary)|||Resigned||09/11/21|||||||
|Professor||R|Andrew|||(General Secretary)|||Appointed||09/11/21|||||||
|Professor||M|Gurnell|||(Treasurer)||||||||||||
|Professor||J H D Bassett||||(Programme<br>Secretary) Resigned||||||09/11/21||||||
|Professor||R|K Sample|||(Programme<br>Secretary) Appointed||||||09/11/21||||||
|Professor||K|Boelaert|||||||||||||||
|Dr A M Brooke||||||||||||||||||
|Professor||S|Forbes|||||||||||||||
|Dr M Freel||||||||||||||||||
|Dr T M Keamey||||||||||||||||||
|Professor||M|J Korbonits|||Appointed<br>09/11/21||||||||||||
|Professor||G|G Lavery|||||||||||||||
|Dr D A Ress||||||||||||||||||
|Professor||R|M Reynolds|||||||||||||||
|Senior Staff:||||||||||||||||||
|I Russell||||||(Chief Executive<br>&|Company|||Secretary)||||||||
|D Mills||||||(Finance Director)||||||||||||
|L Udakis||||||(Director of Membership|||Engagement)|||||||||
|M Hook||||||(HR & Performance|Director)|||||||||||
|R Cropley||||||(Operations<br>Director)||||||||||||
|K Sargent||||||(Deputy Managing|Director, Bioscientiiica)|||||||||||
|||||||No staff are registered|||as directors|||ofthe||Society for Endocrinology||at||
|||||||Companies<br>House.|The term|||'director'|||is|used for internal|purposes|only.||
|Independent|||Auditor:|||Haysmacintyre<br>LLP||||||||||||
|||||||10Queen Street Place||||||||||||
|||||||London||||||||||||
|||||||EC4R 1AG||||||||||||





## 

## 



## 

## 

## 



## 

## 



## 

## 



## 

## 

## 

## 



## 

||||Applications|Awarded|Value (8)|
|---|---|---|---|---|---|
|Conference<br>grants|||124|110|50,397|
|SfE BESfree places|||33|29|9,326|
|Early career grants|||42|21|183,847|
|Summer<br>studentships|||14|7|20,940|
|Patient support grants|||7|7|3,394|
|Public engagement|grants||3|3|2,670|
|Undergraduate<br>achievement||awards|2|6|1,800|
|Practical skills grants|||9|3|5,958|
|Equipment<br>grants|||6|1|9,700|
|Clinical department|grants||14|5|4,400|
|Meeting Support Grants|||5|5|39,825|
|Other grants|||0|1|4,950|
|Total|||259|198|337,207|



## 



## 

## 

|Journal||2017|2018|2019|2020|2021|
|---|---|---|---|---|---|---|
|Journal of|Endocrinology|4.706|4.012|4.381|4.041|4.286|
|Journal of|Molecular Endocrinology|3.577|3.297|3.744|3.562|5.098|
|Endocrine-Related<br>Cancer||5.267|5.331|4.774|4.800|5.678|
|Endocnne|Connections|2.541|3.041|2.474|2.592|3.335|



## 

## 



## 

## 

## 



## 

## 




## 

## 

## 

## 

## 

## 



## 

## 

## 

## 



## 

## 

## 

## 

## 



## 



## 

## 

## 



## 

## 

## 

## 



## 

## 



## 

## 

## 



||||||||||Yearended|
|---|---|---|---|---|---|---|---|---|---|
|||||Year ended||31 December 2021|||31 December<br>2020|
|||||Unrestricted<br>Funds|Restricted<br>Funds||Total Funds||Total Funds|
||||Note|f000||9000||6000|f000|
|income from:||||||||||
|Charitable<br>activities||||2,504||292||2,796|2,146|
|Other trading<br>activities||||3,194||||3,194|3,105|
|Investments||||86||||93|84|
|Other||||130||||130|145|
|Total||||5,914||299||6,213|5,480|
|Expenditure<br>on:||||||||||
|Raising funds||||3,346||||3,346|3,424|
|Charitable<br>activities||||2,394||75||2,469|1,937|
|Other||||21||2||23|21|
|Total||||5,761||77||5,838|5,382|
|Net (losses)/gains|on investments|||400||22||422|58|
|Net (expenditure)/Income||||553||244||797|156|
|Transfers<br>between||funds||20||(20)||||
|Net Movement<br>in|funds|||573||224||797|156|
|Reconciliation<br>of|funds:|||||||||
|Total funds<br>brought||forward||5,599||331||5,930|5,774|
|Total funds canied||forward||6,172||555||6,727|5,930|





## 

## 

|||||||2021|2021|2020|2020|
|---|---|---|---|---|---|---|---|---|---|
|||||||Group|Company|Group|Company|
||||||Note|f000|f000|f000|f000|
|Fixed Assets:||||||||||
|Intangible<br>assets|||||12|1|1|21|21|
|Tangible assets|||||13|1,805|1,805|1,881|1,881|
|Investments|||||14|4,660|4,660|4,114|4,114|
|Investment<br>in Bioscientifica||||Limited||||||
|Total fixed assets||||||6,466|6,467|6,016|6,017|
|Current Assets||||||||||
|Debtors|||||15|1,751|356|2,055|498|
|Cash at bank and|in|hand|||16|2,430|1,369|2,147|996|
|Total current assets||||||4,181|1,725|4,202|1,494|
|Liabilities:||||||||||
|Creditors: Amounts<br>within one year||falling||due|17|3,168|762|3,507|849|
|Net current assets||||||1,013|963|695|645|
|Total assets less current|||liabilities|||7,479|7,430|6,711|6,662|
|Long term loans|||||18|752|752|781|781|
|Net assets||||||6,727|6,678|5,930|5,881|
|The funds ofthe|charity:|||||||||
|Restricted<br>income|funds||||19|555|555|331|331|
|Unrestricted<br>funds|||||20|6,172|6, 123|5,599|5,550|
|Total charity funds||||||6,727|6,678|5,930|5,881|



## 

## 



## 

||||Year|Year|
|---|---|---|---|---|
||||ended|ended|
||||31/12/21|31/12/20|
|||Note|8000|8000|
|Cash flows from operating<br>activities:|||||
|Net cash provided<br>by /(used<br>in) operating|activities||344|131|
|Cash flows from investing<br>activities:|||||
|Dividends<br>and interest|||93|84|
|Purchase<br>of property,<br>plant and equipment|||(1)|(5)|
|Proceeds from sale of investments|||1,062|1,126|
|Purchase<br>of investments|||(1,175)|(1,305)|
|Movement<br>In cash awaitIng<br>investment|||(11)|(62)|
|Net cash provided<br>by investing<br>activities|||(32)|(162)|
|Sale of property asset held for resale|||||
|Noncash<br>movement<br>in Long Term Loans|||(29)|(31)|
|Change<br>in cash and cash equivalents<br>in the <br>period|reporting||283|(62)|
|Cash and cash equivalents<br>at the beginning<br>reporting<br>period|ofthe||2,147|2,209|
|Cash and cash equivalents<br>at the end of the reporting<br>period|||2,430|2,147|
|a)<br>Reconciliation<br>of net Income to net cash flow from operating|||||
|activities|||||
|Net (expenditure)/income<br>for the year (as <br>financial<br>activities)|per the statement|of|797|156|
|AdJustments<br>for:|||||
|Depreciation<br>and amortisation<br>charges|||97|118|
|Gains on investments|||(422)|(58)|
|Dividends<br>and interest from investments|||(93)|(84)|
|Decrease/(Increase)<br>in debtors|||304|(131)|
|(Decrease) /Increase<br>in creditors|||(339)|130|
|Net cash provided<br>by operating<br>activities|||344|131|
|b) Analysis ofcash and cash equivalents|||||
|Cash in hand|||535|756|
|Notice deposits (less than 3 months)|||1,895|1,391|
|Total cash and cash equivalents|||2,430|2,147|





||1|January|Cash|Other non-|Other non-|31 December|
|---|---|---|---|---|---|---|
|||2021|Flows|cash|changes|2021|
|||f000|f000||f000|f000|
|Cash||2,147|283|||2,430|
|Borrowings|||||||
|Debt due within one year||(37)|33||(29)|(33)|
|Debt due alter one year||(781)|||29|(752)|
|||(818)|33|||(785)|
|||1,329|316|||1,645|





## 

## 

## 



## 

## 

## 

## 



## 

## 

## 

## 

## 



## 

## 

|n analy|sis of Group income by geographical<br>loc|ation<br>Is given below:||
|---|---|---|---|
|||Yearto|Year to|
|||31/12/21|31/12/20|
|||0/|0/|
|United|Kingdom|28|21|
|Europe||42|42|
|North America||10|9|
|Rest of|the Wodd|20|28|
|||100|100|



|Summary<br>profit and loss account|Summary<br>profit and loss account|Year to<br>31/12/21|Year to<br>31/12/20|
|---|---|---|---|
|||6000|f000|
|Turnover||5,136|5,066|
|Cost ofsales||(2,808)|(2,772)|
|Gross profit||2,328|2,294|
|Administration||(1,105)|(1,185)|
|Operating<br>profit||1,223|1,109|
|Interest receivable|and similar income|26|32|
|Profit on ordinary|activities|1,249|1,141|
|Gift Aid||(1,249)|(1,324)|
|Profit before taxation|||(183)|
|Taxation||||
|Retained<br>in subsidiary|||(183)|
|Total assets and|liabilities of|Yearto|Year to|
|the subsidiary<br>were:||31/12/21|31/12/20|
|||f000|f000|
|Fixed assets||||
|Current assets||2,456|2,709|
|Creditors: amounts|falling due|(2,406)|(2,659)|
|Total net assets||50|50|
|Aggregate<br>share capital||50|50|





## 

## 

|||Unrestricted|Restricted|Year to|Year to|
|---|---|---|---|---|---|
|||funds|funds|31/12/21|31/12/20|
|||f000|f000|6000|6000|
|Publications||1,697||1,697|1,776|
|Society events and|conferences (see below)|560||560|199|
|Other membership<br>subscrlptions)|services (including|235||235|171|
|Grants received||12|292|304||
|||2,504|292|2,796|2,146|



|Income|from Socie|ty events a|nd|||
|---|---|---|---|---|---|
|||||Year to|Year to|
|||||31/12/21|31/12/20|
|||||6000|f000|
|The Society annual||meeting||503|173|
|Training|and other|registration|fees|57|26|
|||||560|199|



## 

|5)<br>Inc|ome fro|m ot|her trading<br>activiti|es||||
|---|---|---|---|---|---|---|---|
|||||Unrestricted|Restricted|Year to|Year to|
|||||funds|funds|31/12/21|31/12/20|
|||||FOOO|f000|6000|6000|
|Trading|income|from|subsidiary|3,194||3,194|3,105|



## 

|6)<br>Other|income|||||
|---|---|---|---|---|---|
|||Unrestricted|Restricted|Year to|Year to|
|||funds|funds|31/12/21|31/12/20|
|||FOOO|FOOO|6000|FOOO|
|Royalties|received|130||130|145|





## 

## 

||||||Unrestricted|Restricted|Year to|Year to|
|---|---|---|---|---|---|---|---|---|
||||||funds|funds|31/12/21|31/12/20|
||||||f000|f000|f000|6000|
|Trading|costs|of|subsidiary|company|3,346||3,346|3,424|



## 

|8)<br>Expenditu|re|o|n charita|ble<br>activitie|s|||||
|---|---|---|---|---|---|---|---|---|---|
||||||Direct|Grants|Support|Year to|Year to|
||||||costs|paid|costs|31/12/21|31/12/20|
||||||||(note 9)|||
||||||6000|6000|OOOO|f000|f000|
|Publications|||||567|||567|533|
|Society events|and||conferences||385||248|633|78|
|Other membership<br>subscriptions<br>paid)|||services|(Including|503|366|325|1,194|1,320|
|Society research||projects|||75|||75||
||||||1,530|366|573|2,469|1,937|
|2020|||||Direct<br>costs|Grants<br>paid|Support<br>costs|Yearto<br>31/12/20||
||||||||(note 9)|||
||||||8000|8000|6000|6000||
|Publications|||||533|||533||
|Society events|and||conferences||34|||78||
|Other membership<br>subscrlptlons<br>paid)|||services|(including|453|279|588|1,320||
|Society research||projects||||||||
||||||1,026|279|632|1,937||





## 

## 

|Grants paid are made up as|follows:|||||||
|---|---|---|---|---|---|---|---|
|||||Grants|Staff and|Year to|Year to|
||||No|paid<br>6000|other<br>f000|31/12/21<br>6000|31/12/20<br>f000|
|Grants payable<br>to individuals||||||||
|Travel grants and grants for <br>meetings<br>and conferences|attendance|at|139|60|4|||
|Summer<br>studentships|||7|21||22|29|
|Early career grants|||21|184||188|184|
|Total grants payable toindividuals|||167|265|9|274|213|
|Grants paid toinstitutions:||||||||
|Patient support<br>grants|||||||17|
|Public engagement<br>grants|||||||1|
|Undergraduate<br>achievement|award||||||5|
|Regional clinical cases grants||||||||
|Other grants|||15|64|20|84|63|
|Total grants paid toinstitutions:|||31|72|20|92|86|
|Total grants<br>paid|||198|337|29|366|299|
|Adjustment<br>for Endocrine Academy 2020||||||||
|Conference<br>grants awarded|In 2019but|not|||||(20)|
|paid due to COVID-19||||||||
||||198|337|29|366|279|





## 

||||||||Grants|Staff and|Year to|
|---|---|---|---|---|---|---|---|---|---|
|2020|||||||paid|other costs|31/12/20|
|||||||No|f000|FOOO|6000|
|Grants payable toindividuals||||||||||
|Travel grants||and grants for||attendance|at meetings|||||
|and conferences||||||||||
|Summer<br>studentships||||||11|28|1|29|
|Early career||grants||||19|179|5|184|
|Total grants||payable|toindividuals|||30|207|6|213|
|Grants paid||toinstitutions:||||||||
|Patient support<br>grants||||||8|17||17|
|Public engagement|||grants|||1|1||1|
|Undergraduate<br>achievement||||award||18|5||5|
|Other grants||||||9|59||63|
|Total grants||paid to|institutions:|||36|82|4|86|
|Total grants||paid||||66|289|10|299|
|Adjustment|for Endocrine Academy 2020|||||||||
|Conference||grants awarded||in 2019but|not paid due|(31)|(23)|3|(20)|
|to Covid||||||||||
|||||||35|266|13|279|



## 

|Support co<br>as follows:|s|ts are all directly attributable<br>to charitable<br>|activities as shown<br>in note 8 and are|made up|
|---|---|---|---|---|
||||Year to|Year to|
||||31/12/21|31/12/20|
||||6000|6000|
|Governance|||50|54|
|Finance and||administration|280|290|
|Information||technology|106|110|
|Marketing|and communications||32|32|
|Human<br>resources|||122|83|
|Executive|||170|63|
|VAT Refund|||(187)||
|Total|||573|632|





## 

## 

|This is state|d after ch|arging|:||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|||||||||||Year to||Year to|
|||||||||||31/12/21||31/12/20|
|||||||||||f000||f000|
|Depreciation|and amortisation|||||||||98||117|
|Auditor's<br>remuneration:|||||||||||||
|Group audit|services|||||||||21||18|
|Accountancy|and other services|||||||||4||9|
|11)Staff costs|||||||||||||
|Staff costs during the||year|amounted||to:||||||||
|||||||||||Year to||Year to|
|||||||||||31/12/21f||31/12/20f|
|Salaries||||||||||2,564,497||2,478,828|
|Social|security costs|||||||||254,022||251,651|
|Other pension costs||||||||||287,853||274,481|
|||||||||||3,106,372||3,004,960|
|The number|of employees||whose|remuneration|||was within||the|bands stated was as follows:|||
|||||||||||Yearto||Year to|
|||||||||||31/12/21||31/12/20|
|||||||||||Number||Number|
|f60,001 - F70,000|||||||||||||
|f70,001 - f80,000|||||||||||||
|F120,001 - F130,000|||||||||||||
|The average|number|of full-time||equivalent||employees||analysed||by function was:|||
|||||||||||Year|to|Year to|
|||||||||||31/12/21||31/12/20|
|||||||||||Number||Number|
|Charitable|activities||||||||||56|59|
|Administration|||||||||||22|23|
||||||||||||78|82|



## 



## 

## 

||Group and Company|Group and Company|
|---|---|---|
||Office software|2020|
||f000|f000|
|Cost:|||
|01-Jan-21|255|253|
|Additions||2|
|31-Dec-21|255|255|
|Amortlsatlon|||
|01-Jan-21|234|199|
|Charge for the year|20|35|
|31-Dec-21|254|234|
|Net Book Value|||
|31-Dec-21||21|
|13)Tangible assets|||
|Group and Company|||



|13)Tangible assets<br>Group and Company||||||||
|---|---|---|---|---|---|---|---|
||Freehold|land|Fixtures|Office|Company|Development|Group|
||and buildings||and|equipment|total|costs|total|
||||fittings|||||
|||f000|f000|f000|f000|f000|f000|
|Cost:||||||||
|1 January 2021||1,767|284|444|2,495|37|2,532|
|Additions||||1|1||1|
|Disposals||||||||
|31 December 2021||1,767|264|445|2,496|37|2,533|
|Depreciation||||||||
|1 January 2021||101|123|390|614|37|651|
|Charge for the year||34|27|16|77||77|
|Eliminated<br>on||||||||
|disposals||||||||
|31 December 2021||135|150|406|691|37|728|
|Net Book Value||||||||
|31 December 2021||1,632||39|1,805||1,805|
|31 December 2020||1,666|161|54|1,881||1,881|





## 

## 

|14) Listed|In|vestments||||
|---|---|---|---|---|---|
|||||Group and|Company|
|||||2021|2020|
|||||6000|6000|
|Market value||at 1 January|2021:|3,980|3,742|
|Additions||||1,175|1,305|
|Disposals||||(1,062)|(1,125)|
|Movement|in|cash awaiting|investment|||
|Net unrealised||investment|gains|422|58|
|Market value||at 31 December 2021||4,515|3,980|
|||||Group and|Company|
|||||2021|2020|
|||||6000|6000|
|The market|value at 31 December 2021 comprises:|||||
|Listed investments||||4,515|3,980|
|Cash awaiting||investment||145|134|
|||||4,660|4,114|



## 

|15) Debto|rs||||||
|---|---|---|---|---|---|---|
||||2021||2020||
||||Group|Company|Group|Company|
||||6000|6000|6000|f000|
|Trade and|other debtors||1,175|129|1,514|280|
|Prepayments||and accrued income|570|227|453|218|
|Derivative|Asset||6||88||
||||1,751|356|2,055|498|



## 

|16)Cash at bank and ln hand|||||
|---|---|---|---|---|
|||2021|2020||
||Group|Company|Group|Company|
||FOOO|f000|6000|f000|
|Bank current accounts|533|22|753|22|
|Monies held on deposit|1,895|1,347|1,391|974|
|Petty cash|2||3||
||2,430|1,369|2,147|996|





## 

## 

|17) Cre|ditors:|amo|unts<br>f|allin|g due within one|year|year|||
|---|---|---|---|---|---|---|---|---|---|
|||||||2021|||2020|
|||||||Group|Company|Group|Company|
|||||||f000|8000|6000|6000|
|Bank Loans||||||33|33|37|37|
|Trade creditors||||||242|150|255|29|
|Amounts|due to|subsidiary|||||11||39|
|Clients'|accounts|||||114||73||
|Deferred|income|||||1,247|107|1,225|108|
|Other taxes and||social security||||82|82|90|90|
|Other creditors||and|accruals|||1,450|379|1,827|546|
|||||||3,168|762|3,507|849|
||||||||2021|2020||
|||||||Group|Company|Group|Company|
|||||||8000|8000|8000|f000|
|Deferred|income at||1 January||2021|1,225|108|1,256|122|
|Resources deferred|||in the|year||1,247|107|1,225|108|
|Amounts|taken|to income||in the||(1,225)|(108)|(1,256)|(122)|
|Deferred|income at||31 December 2021|||1,247|107|1,225|108|



## 



## 

## 

||||||Group|and Company|and Company|
|---|---|---|---|---|---|---|---|
|||||||2021|2020|
|||||||f000|FOOO|
|Loan|repayment|year|1|||33|37|
|Loan|repayment|years||2-5||151|147|
|Loan|repayment|years||5+||601|634|
|||||||785|818|



## 

|2021|Balance at|Movement|in resources|Transfer|Investment|Balance at 31|
|---|---|---|---|---|---|---|
|Group and|1 January|Income|Expenditure|between|gains/|December|
|company|2021|||funds|(losses)|2021|
||FOOO|f000|f000|f000|f000|f000|
|CaHASE Fund|||||||
|Anti-Thyroid|||||||
|Drug Study|||||||
|ACC Service|||||||
|Improvement|||(4)||||
|Marjorie<br>Robinson<br>Fund|327||(3)|(20)|22|333|
|Obesity<br>Database|||(69)|||185|
|Endocrine<br>Nurse|||||||
|Network||||||10|
|Besins Service||20||||20|
|Improvement|||||||
||331|299|(77)|(20)|22|555|
|2020|Balance at|Movement|in resources|Transfer|Investment|Balance at 31|
|Group and|1 January|Income|Expenditure|between|gains/|December|
|company|2020|||funds|(losses)|2020|
||f000|f000|f000|FOOO|f000|f000|
|CaHASE Fund|||(2)||||
|Anti-Thyroid<br>Drug Study|||(4)||||
|Marjorie<br>Robinson<br>Fund|359||(2)|(20)|(18)|327|
||370|7|(8)|(20)|(18)|331|





## 

## 

|2021||Balance|Movement|Movement|in|Transfer|Investment|Balance at|
|---|---|---|---|---|---|---|---|---|
|||at 1|resources|||between|gains/(losses)|31|
|||January|Income|Expenditure||funds||December|
|||2021||||||2021|
|||f000|f000||f000|f000|f000|f000|
|Company||5,550|1,023||(1,848)|998|400|6,123|
|Bioscientifica<br>Limited||49|4,891||(3,913)|(978)||49|
|Group tot aI||5,599|5,914||(5,761)|20|400|6,172|
|Bioscientifica|Limited|profits off1,249k were||transferred<br>to the||Company|as gift aid (2020|f1,141k).|
|2020||Balance|Movement||in|Transfer|Investment|Balance at|
|||at 1|resources|||between|gatns/(losses)|31|
|||January|Income|Expenditure||funds||December|
|||2020||||||2020|
|||f000|f000||f000|f000|f000|f000|
|Company||5,172|589||(1,416)|1,129|76|5,550|
|Bioscientifica<br>Limited||232|4,883||(3,957)|(1,109)||49|
|Group total||5,404|5,472||(5,373)|20|76|5,599|





## 

|21)Analysis of Group and Company|21)Analysis of Group and Company|net assets between funds||||
|---|---|---|---|---|---|
|||Unrestricted<br>funds|Restricted<br>Funds|2021|2020|
|||FOOO|E'000|FOOO|6000|
|Intangible<br>fixed assets||1||1|21|
|Tangible<br>fixed assets||1,805||1,805|1,881|
|Listed Investments||4,284|376|4,660|4,114|
|Debtors||1,572|179|1,751|2,055|
|Cash at bank and|in hand|2,430||2,430|2,147|
|Creditors||(3,168)||(3,168)|(3,507)|
|Long term loans||(752)||(752)|(781)|
|||6,172|555|6,727|5,930|
|Company||Unrestricted<br>funds|Restricted<br>Funds|2021|2020|
|||f000|FOOO|FOOO|f000|
|Fixed assets||1,806||1,806|1,902|
|Listed Investments||4,284|376|4,660|4,114|
|Investment<br>in Subsidiary||||1|1|
|Debtors and Cash||1,546|179|1,725|1,494|
|Creditors||(762)||(762)|(849)|
|Long term loans||(752)||(752)|(781)|
|||6,123|555|6,678|5,881|
|Group 2020||Unrestricted<br>funds|Restricted<br>Funds|2020||
|||8000|6000|6000||
|Fixed assets||1,902||1,902||
|Listed Investments||3,758|356|4,114||
|Debtors and Cash||4,227|(25)|4,202||
|Creditors||(3,507)||(3,507)||
|Long term loans||(781)||(781)||
|||5,599|331|5,930||
|Company 2020||Unrestricted<br>funds|Restricted<br>Funds|2020||
|||ZOOO|8000|FOOO||
|Fixed assets||1,902||1,902||
|Listed Investments||3,758|356|4,114||
|Investment<br>in Subsidiary||||||
|Debtors and Cash||1,519|(25)|1,494||
|Creditors||(849)||(849)||
|Long term loans||(781)||(781)||
|||5,550|331|5,881||





## 

## 

|2) Transfer between<br>funds||||||
|---|---|---|---|---|---|
|||||2021|2020|
|During the year the following|transfers|were made between|funds:|||
|From the Marjor/e<br>Robinson|Fund to:|||||
|Main Fund to provide<br>early|career research grants|||20 000|20 000|



## 

## 



## 

## 

## 

||||||Year ended|31/12/21|Year ended|31/12/20|
|---|---|---|---|---|---|---|---|---|
|||||Note|f000|f000|FOOO|f000|
|Income from activities:|||||||||
|Membership<br>subscriptions|||||151||146||
|Event income|||||542||161||
|Royalties receivable|||||146||165||
|Advertising<br>income|||||||0||
|Sundry income|||||98||43||
|||||||937||515|
|Expenditure<br>on activities:|||||||||
|Divisional<br>Salaries|||||340||327||
|Publishing<br>costs|||||18||20||
|Venue and catering costs|||||317||11||
|Bioscientiffca management|||fees||260||215||
|Programmes,<br>abstracts||and|handbooks||17||6||
|Expenses|||||74||26||
|Marketing|||||13||16||
|Other direct expenses|||||91||60||
|Grants|||||337||265||
|||||||1 462||946|
|Deficit from activities<br>Overheads||||||(530)||(431)|
|Salaries|||||604||486||
|Other staff costs|||||127||99||
|Staff expenses|||||16||10||
|Premises costs|||||143||142||
|Insurance|||||23||27||
|Professional<br>fees|||||20||19||
|Investment<br>manager's|fees||||21||19||
|Printing,<br>postage,<br>stationery|||and||3||5||
|Depreciation|||||98||117||
|General tax write<br>Off|||||(189)||0||
|Marketing|||||1||0||
|Bank and credit card charges|||||19||19||
|Sundry office expenses|||||30||29||
|Recharged|||||(264)||(2884||
|||||||662||684|
|Deficit from Main Fund||before|||||||
|investment<br>income and gains on||||||(1,182)||(1,115)|
|Investments<br>(carried|forward)||||||||





## 

## 

|||||Year ended|31/12/21|Year ended|31/12/20|
|---|---|---|---|---|---|---|---|
||||Note|8000|8000|8000|f000|
|Deficit from|Main Fund before|||||||
|Investment|income and gains|on|||(1,182)||(1,115)|
|Investments|(brought<br>forward)|||||||
|Income from|listed investments|||86||75||
|Bank deposit|interest|||||0||
|Gift aid from|Bioscientifica<br>Limited|||1,249||1,324||
||||||1,335||1,399|
|(Deficit) / Surplus<br>prior to transfers|||||153||284|
|Transfers<br>from<br>/ (to) designated||funds|||(20)||20|
|Surplus<br>from|unrestricted<br>fund before||||173||304|
|gains on Investments||||||||
|Net gains/(losses)<br>on investments|||||400|||
|Total surplus<br>/ (deficit) for the||year|||573||380|





## 

## 

|||||||2021|||2020|
|---|---|---|---|---|---|---|---|---|---|
|||||Note|6000|FOOO||OOOO|E'000|
|Fixed Assets||||||||||
|Intangible<br>assets|||||||1||21|
|Tangible assets||||||1,805|||1,881|
|Listed investments||||||4,284|||3,758|
|Investment<br>In Bioscientifica|||Limited||||1|||
|||||||6,091|||5,661|
|Current assets||||||||||
|Debtors and prepayments|||||356|||498||
|Bloscientifica<br>Limited|||||(11)|||(39)||
|Cash at bank and||In hand|||1,369|||996||
||||||1,714|||1,455||
|Current<br>liabilities||||||||||
|Income<br>in advance|||||107|||108||
|Creditors<br>and accruals|||||644|||538||
|Long term loans|||||751|||781||
|Obesity database|||||185|||165||
|Marjorie Robinson||Fund|||(43)|||(31)||
|CaHASE Fund|||||1|||1||
|Anti Thyroid<br>Drug||Study|||3|||4||
|ACC Service Improvement|||Fund||4|||||
|Endocrine<br>Nurse|Network||Fund||10|||||
|Besins Research|Fund||||20|||||
||||||1,682|||1,566||
|Net Current Assets|||||||32|||
|Total assets less||cunent|liabilities|||6,|123||5,550|
|Financed<br>by:||||||||||
|Unrestricted<br>Fund||||19||6,123|||5,550|





## 

## 

## 

||||||Year ended|Year ended|
|---|---|---|---|---|---|---|
||||||31/12/21|31/12/20|
||||Note||f000|f000|
|Listed investment|Income||||||
|Interest received|||||||
|Expenditure<br>on activities:|||||||
|Grants<br>paid|||||20|20|
|Investment<br>managers'||fees|||(2)|2|
||||||18|22|
|Deficit before gains /(losses)|||on investment||(11)|(15)|
|Gains<br>/ (losses) on investments|||||22|(18)|
|Surplus for the year||||||(33)|
|Balance sheet at|31|December 2021|||||
||||||2021|2020|
|Fixed Assets|||||||
|Listed investments|||||376|356|
|Current assets|||||||
|Main Fund —current||account|||(43)|(31)|
|Net assets|||||333|325|
|Financed<br>by:|||||||
|Marjorie Robinson|Fund|||18|333|325|





## 

## 

|||||Year ended|Yearended|
|---|---|---|---|---|---|
|||||31/12/21|31/12/20|
|||Note||f000|f000|
|Income|from activities:|||||
|Grants received||||||
|Expenditure<br>on activities:||||||
|General|expenses|||||
|Management<br>charge||||||
|Surplus|/ {Deficit)for the year||||(2)|
|Balance|sheet at 31 December 2021|||||
|||||2021|2020|
|Current|assets|||||
|Main Fund —current account||||||
|Net current assets||||||
|Financed|by:|||||
|CaHASE|Fund||18|||





## 

## 

||||Year ended|Year ended|
|---|---|---|---|---|
||||31/12/21|31/12/20|
||Note||f000|E000|
|Income from activities:|||||
|Grants received|||||
|Expenditure<br>on activities:|||||
|General expenses|||||
|Management<br>charge||||(4)|
|||||(4)|
|Surplus<br>/ (Deficit) for the year|||||
|Balance sheet at 31 December 2021|||||
||||2021|2020|
||||8000|EOOO|
|Current assets|||||
|Main Fund —current account|||||
|Net current assets|||||
|Financed<br>by:|||||
|Anti Thyroid Study Fund||19|||





## 

## 

|||||Year ended|
|---|---|---|---|---|
|||||31/12/21|
|||Note||OOOO|
|Income from activities:|||||
|Grants received|||||
|Expenditure<br>on activities:|||||
|General expenses|||||
|Management<br>charge|||||
|Surplus<br>/ (Deficit) forthe|year||||
|Balance sheet at 31 December 2021|||||
|||||2021|
|||||f000|
|Current assets|||||
|Main Fund —current account|||||
|Net current assets|||||
|Financed<br>by:|||||
|ACC Service Improvement|Fund||19||





## 

## 

||||Year ended|
|---|---|---|---|
||||31/12/21|
||Note||6000|
|Income from activities:||||
|Grants received|||254|
|Expenditure<br>on activities:||||
|Development<br>costs|||66|
|Management<br>charge|||3|
||||69|
|Surplus<br>/ (Deficit) for the year|||185|
|Balance sheet at 31 December 2021||||
||||2021|
||||f000|
|Currentassets||||
|Main Fund —current account|||185|
|Net current assets|||185|
|Financed<br>by:||||
|Obesity Database Project Fund||19||





|||||Year ended|
|---|---|---|---|---|
|||||31/12/21|
|||Note||f000|
|Income from activities:|||||
|Grants received||||10|
|||||10|
|Expenditure<br>on activities:|||||
|General expenses|||||
|Management<br>charge|||||
|Surplus<br>/ (Deficit) for the|year|||10|
|Balance sheet at 31 December 2021|||||
|||||2021|
|||||f000|
|Current assets|||||
|Main Fund —current account||||10|
|Net current assets||||10|
|Financed by:|||||
|Endocrine<br>Nurse<br>Network|Fund||19|10|





## 

|||||Year ended|
|---|---|---|---|---|
|||||31/12/21|
|||Note||f000|
|Income from activities:|||||
|Grants received||||20|
|||||20|
|Expenditure<br>on activities:|||||
|General expenses|||||
|Management<br>charge|||||
|Surplus<br>/ (Deficit) for the year||||20|
|Balance sheet at 31 December 2021|||||
|||||2021|
|||||FOOO|
|Current assets|||||
|Main Fund —current account||||20|
|Net current assets||||20|
|Financed<br>by:|||||
|Besins Service Improvement|Fund||19|20|